Umlobi: Virginia Floyd
Usuku Lokudalwa: 13 Agasti 2021
Ukuvuselela Usuku: 15 Unovemba 2024
Anonim
why the ordinary niacinamide 10% + zinc 1% is causing purging and breakouts 😅
Ividiyo: why the ordinary niacinamide 10% + zinc 1% is causing purging and breakouts 😅

-Delile

Kunezinhlobo ezimbili zikavithamini B3. Enye ifomu i-niacin, enye i-niacinamide. INiacinamide itholakala ekudleni okuningi okubandakanya imvubelo, inyama, inhlanzi, ubisi, amaqanda, imifino eluhlaza, ubhontshisi nezinhlamvu zokusanhlamvu. I-Niacinamide nayo itholakala kuma-supplements amaningi ka-vitamin B anama-vitamin B. I-Niacinamide nayo ingakhiwa emzimbeni kusuka ku-niacin yokudla.

Musa ukudida i-niacinamide ne-niacin, i-NADH, i-nicotinamide riboside, i-inositol nicotinate, noma i-tryptophan. Bona izinhlu ezihlukile zalezi zihloko.

I-Niacinamide ithathwa ngomlomo ukuvikela ukushoda kwe-vitamin B3 nezimo ezihlobene nayo njenge-pellagra. Iphinde ithathwe ngomlomo ngenxa yezinduna, isifo sikashukela, umdlavuza womlomo, i-osteoarthritis, nezinye izimo eziningi. Noma kunjalo, abukho ubufakazi obuhle besayensi obusekela lokhu kusetshenziswa.

I-Niacinamide iyasetshenziswa nasesikhumbeni sezinduna, i-eczema, nezinye izimo zesikhumba. Abukho futhi nobufakazi obuhle bokuxhasa lokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze NIACINAMIDE zimi kanje:


Cishe iyasebenza ...

  • Isifo esibangelwa ukuntuleka kwe-niacin (pellagra). I-Niacinamide ivunyelwe yi-U.S. Food and Drug Administration (FDA) ngalokhu kusetshenziswa. I-Niacinamide kwesinye isikhathi iyathandwa kune-niacin ngoba ayibangeli "ukuqhuma," (ububomvu, ukulunywa nokushoshozela), umphumela ohlangothini wokwelashwa kwe-niacin.

Kungenzeka kusebenze ...

  • Izinduna. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha amaphilisi aqukethe i-niacinamide nezinye izithako amasonto ayi-8 kuthuthukisa ukubukeka kwesikhumba kubantu abanezinduna. Olunye ucwaningo lukhombisa ukuthi ukufaka ukhilimu oqukethe i-niacinamide kuthuthukisa ukubukeka kwesikhumba kubantu abanezinduna.
  • Isifo sikashukela. Olunye ucwaningo lukhombisa ukuthi ukuthatha i-niacinamide kungasiza ekuvimbeleni ukulahleka komkhiqizo we-insulin ezinganeni nakubantu abadala abasengozini yesifo sikashukela sohlobo 1. Kungavimbela nokulahleka kokukhiqizwa kwe-insulin futhi kwehlise nomthamo we-insulin odingwa yizingane ezisanda kutholakala zine-1 yesifo sikashukela. Kodwa-ke, i-niacinamide akubonakali ivimbela ukukhula kohlobo lwesifo sikashukela sohlobo 1 ezinganeni ezisengozini. Kubantu abanesifo sikashukela sohlobo lwesibili, i-niacinamide ibonakala isiza ukuvikela ukukhiqizwa kwe-insulin futhi ithuthukise ukulawulwa kukashukela egazini.
  • Izinga eliphakeme le-phosphate egazini (hyperphosphatemia). Izinga eliphakeme legazi le-phosphate lingabangelwa ukunciphisa ukusebenza kwezinso. Kubantu abanokwehluleka kwezinso abaku-hemodialysis futhi abanamazinga aphezulu we-phosphate yegazi, ukuthatha i-niacinamide kubonakala kusiza ukwehlisa amazinga e-phosphate lapho kuthathwa nge-binders ye-phosphate noma ngaphandle kwayo.
  • Umdlavuza wekhanda nentamo. Ucwaningo lukhombisa ukuthi ukuthatha i-niacinamide ngenkathi uthola i-radiotherapy kanye nohlobo lokwelashwa olubizwa nge-carbogen kungasiza ekulawuleni ukukhula kwesimila futhi kwandise ukusinda kwabanye abantu abanomdlavuza we-larynx. Ukuthatha i-niacinamide ngenkathi uthola i-radiotherapy ne-carbogen kubonakala kuzuzisa abantu abanomdlavuza we-larynx nabo abane-anemic. Kubukeka sengathi kusiza abantu abanezimila ezincishwa umoya-mpilo.
  • Umdlavuza wesikhumba. Ukuthatha i-niacinamide kubonakala kusiza ukuvimbela umdlavuza omusha wesikhumba noma izindawo ezingapholi kahle (i-actinic keratosis) ekwakheni kubantu abanomlando womdlavuza wesikhumba noma i-actinic keratosis.
  • I-osteoarthritis. Ukuthatha i-niacinamide kubonakala kuthuthukisa ukuguquguquka kokuhlanganyela futhi kwehlise ubuhlungu nokuvuvukala kubantu abane-osteoarthritis. Futhi, abanye abantu abane-osteoarthritis abathatha i-niacinamide bangadinga ukuphuza imishanguzo yezinhlungu.

Kungenzeka kungasebenzi ku ...

  • Isigaxa sobuchopho. Ucwaningo lokuqala lubonisa ukuthi ukwelapha abantu abanezicubu zobuchopho ezisuswe ngokuhlinzwa nge-niacinamide, i-radiotherapy, ne-carbogen akukwenzi ngcono ukusinda uma kuqhathaniswa ne-radiotherapy noma i-radiotherapy ne-carbogen.
  • Umdlavuza wesinye. Ukwelapha abantu abanomdlavuza wesinye nge-niacinamide, i-radiotherapy, ne-carbogen akubonakali kunciphisa ukukhula kwesimila noma kuthuthukisa ukusinda uma kuqhathaniswa ne-radiotherapy noma i-radiotherapy ne-carbogen.

Ubufakazi obanele bokukala ukusebenza kwe ...

  • Isifo samehlo esiholela ekulahlekelweni kombono kubantu abadala (ukuwohloka okuhlobene nobudala noma i-AMD). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha i-niacinamide, i-vitamin E, ne-lutein unyaka kuthuthukisa ukuthi i-retina isebenza kahle kangakanani kubantu abalahlekelwe umbono ngenxa yobudala be-retina.
  • Isikhumba esiguga. Ucwaningo lwakuqala lukhombisa ukuthi ukusebenzisa ukhilimu oqukethe u-5% niacinamide ebusweni kuthuthukisa ubumhlophe, imibimbi, ukuqina, nokubomvu kubantu besifazane abanesikhumba esigugayo ngenxa yokulimala kwelanga.
  • I-eczema (i-atopic dermatitis). Ucwaningo lwakuqala lukhombisa ukuthi ukufaka ukhilimu oqukethe i-2% niacinamide kunciphisa ukulahleka kwamanzi futhi kuthuthukise ukufuthwa kwamanzi, futhi kunciphisa ububomvu nokukala, kubantu abane-eczema.
  • Ukunakwa kokushoda-i-hyperactivity disorder (ADHD). Kunobufakazi obuphikisanayo ngokusebenziseka kwe-niacinamide ngokuhlangana namanye amavithamini ekwelashweni kwe-ADHD.
  • Ukubomvu kwesikhumba okubangelwa ukulimala noma ukucasuka (i-erythema). Ucwaningo lwakuqala lukhombisa ukuthi ukufaka ukhilimu oqukethe i-niacinamide kunciphisa ukubomvu kwesikhumba, ukoma, nokunwaya okubangelwa umuthi wezinduna i-isotretinoin.
  • Isifo sezinso sesikhathi eside (isifo sezinso esingalapheki noma i-CKD). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacinamide akusizi ukunciphisa ukuncipha kwabantu abanezifo zezinso.
  • Amabala wesikhumba amnyama ebusweni (i-melasma). Ucwaningo lwakuqala lukhombisa ukuthi ukufaka amafutha okuthambisa aqukethe u-5% niacinamide noma u-2% niacinamide ane-2% tranexamic acid amasonto ama-4-8 kusiza ukukhanyisa isikhumba kubantu abanezikhumba ezimnyama.
  • Umdlavuza oqala kumaseli amhlophe egazi (non-Hodgkin lymphoma). Ucwaningo lokuqala lubonisa ukuthi ukuthatha i-niacinamide njengengxenye yokwelashwa ngomuthi obizwa nge-vorinostat kungasiza abantu abane-lymphoma ukuthi bangene ekuxolelweni.
  • Isimo sesikhumba esidala ubomvu ebusweni (i-rosacea). Ucwaningo lokuqala lubonisa ukuthi ukuthatha amaphilisi aqukethe i-niacinamide nezinye izithako amasonto ayi-8 kuthuthukisa ukubukeka kwesikhumba kubantu abane-rosacea.
  • Isikhumba esibuhlungu, esinesikhumba ekhanda nasebusweni (seborrheic dermatitis). Ucwaningo lwakuqala lukhombisa ukuthi ukufaka ukhilimu oqukethe i-niacinamide engu-4% kunganciphisa ukubomvu nokukhula kwesikhumba kubantu abane-seborrheic dermatitis.
  • Ukuphuza ngokweqile.
  • Isifo i-Alzheimer.
  • Isifo samathambo.
  • Nciphisa amakhono okukhumbula nawokucabanga avela ngokujwayelekile ngeminyaka.
  • Ukucindezeleka.
  • Umfutho wegazi ophezulu.
  • Ukugula kokunyakaza.
  • I-Premenstrual syndrome (i-PMS).
  • Ezinye izimo.
Kudingeka ubufakazi obuningi ukukala i-niacinamide yalokhu kusetshenziswa.

I-Niacinamide ingenziwa nge-niacin emzimbeni. INiacin iguqulwa ibe yi-niacinamide lapho ithathwa ngamanani amakhulu kunalokho okudingeka emzimbeni. I-Niacinamide ichithwa kalula emanzini futhi ifakwa kahle lapho ithathwa ngomlomo.

I-Niacinamide iyadingeka ekusebenzeni kahle kwamafutha noshukela emzimbeni nokugcina amaseli aphilile.

Ngokungafani ne-niacin, i-niacinamide ayinayo imiphumela ezuzisayo emafutheni futhi akufanele isetshenziselwe ukwelapha i-cholesterol ephezulu noma amazinga aphezulu wamafutha egazini. Lapho ithathwa ngomlomo: Niacinamide kuyinto CISHE UVIKILE kubantu abadala abaningi lapho bethathwa ngamanani anconyiwe. Ngokungafani ne-niacin, i-niacinamide ayibangeli ukuqhuma. Kodwa-ke, i-niacinamide ingadala imiphumela emibi efana nesisu, igesi, isiyezi, ukuqubuka, ukulunywa nezinye izinkinga. Ukunciphisa ubungozi bale miphumela emibi, abantu abadala kufanele bagweme ukuthatha i-niacinamide ngemithamo emikhulu kuno-35 mg ngosuku.

Lapho kuthathwa imithamo engaphezu kuka-3 amagremu ngosuku lwe-niacinamide, imiphumela emibi kakhulu ingenzeka. Lokhu kufaka phakathi izinkinga zesibindi noma ushukela ophakeme wegazi.

Lapho isetshenziswa esikhunjeni: Niacinamide kuyinto OKUNGENZEKA UKUPHEPHA. Ukhilimu we-Niacinamide ungadala ukushisa okuncane, ukulunywa, noma ubomvu.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Niacinamide kuyinto CISHE UVIKILE kwabesifazane abakhulelwe nabancelisayo lapho bethathwa ngamanani anconyiwe. Inani eliphakanyisiwe le-niacin labesifazane abakhulelwe noma abancelisa ibele lingu-30 mg ngosuku kwabesifazane abangaphansi kweminyaka engu-18 ubudala, kanye no-35 mg ngosuku kwabesifazane abaneminyaka engaphezu kwengu-18 ubudala.

Izingane: Niacinamide kuyinto CISHE UVIKILE lapho ithathwa ngomlomo ngamanani anconyiwe eqembu ngalinye leminyaka. Kepha izingane kufanele zigweme ukuthatha imithamo ye-niacinamide ngaphezu kwemikhawulo engenhla yansuku zonke, eyi-10 mg yezingane ezineminyaka engu-1-3 ubudala, i-15 mg yezingane ezineminyaka engu-4-8 ubudala, i-20 mg yezingane ezineminyaka engu-9-13 ubudala, futhi 30 mg wezingane ezineminyaka engu-14-18 ubudala.

Ukungezwani komzimba: I-Niacinamide ingenza ukungezwani komzimba kube nzima kakhulu ngoba kubangela ukuthi ikhishwe i-histamine, ikhemikhali elibhekele izimpawu zomzimba.

Isifo sikashukela: I-Niacinamide ingakhuphula ushukela wegazi. Abantu abanesifo sikashukela abathatha i-niacinamide kufanele bahlole ushukela egazini labo ngokucophelela.

Isifo se-gallbladder: I-Niacinamide ingenza isifo se-gallbladder sibe sibi kakhulu.

Gout: Inani elikhulu le-niacinamide lingaletha ku-gout.

I-dialysis yezinso: Ukuthatha i-niacinamide kubonakala kukhulisa ubungozi bamazinga aphansi eplatelet yegazi kubantu abanezinso ezihluleka ukusebenza nge-dialysis.

Isifo sesibindi: I-Niacinamide ingakhuphula ukulimala kwesibindi. Ungayisebenzisi uma unesifo sesibindi.

Izilonda zesisu noma zamathumbu: I-Niacinamide ingenza izilonda zibe zimbi kakhulu. Ungayisebenzisi uma unezilonda.

Ukuhlinzwa: I-Niacinamide ingaphazamisa ukulawulwa kukashukela egazini ngesikhathi nangemva kokuhlinzwa. Yeka ukuthatha i-niacinamide okungenani amasonto ama-2 ngaphambi kokuhlinzwa okuhleliwe.

Maphakathi
Qaphela ngale nhlanganisela.
I-Carbamazepine (Tegretol)
ICarbamazepine (Tegretol) yehliswa ngumzimba. Kunokukhathazeka okuthile ngokuthi i-niacinamide ingahle yehle ukuthi umzimba wephula kanjani ngokushesha i-carbamazepine (Tegretol). Kepha alukho ulwazi olwanele ukwazi ukuthi ngabe lokhu kubalulekile.
Imithi engalimaza isibindi (izidakamizwa ze-Hepatotoxic)
I-Niacinamide ingalimaza isibindi, ikakhulukazi uma isetshenziswa ngemithamo ephezulu. Ukuthatha i-niacinamide kanye nemithi engalimaza nesibindi kungakhuphula ubungozi bokulimala kwesibindi. Ungathathi i-niacinamide uma uthatha umuthi ongalimaza isibindi.

Eminye imishanguzo engalimaza isibindi ifaka i-acetaminophen (Tylenol neminye), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporaconazole) i-erythromycin (i-Erythrocin, i-Ilosone, abanye), i-phenytoin (i-Dilantin), i-lovastatin (i-Mevacor), i-pravastatin (i-Pravachol), i-simvastatin (i-Zocor), nezinye eziningi.
Imithi eyehlisa ukunqamuka kwegazi (Anticoagulant / Antiplatelet drug)
I-Niacinamide inganciphisa ukuvimba kwegazi. Ukuthatha i-niacinamide kanye nemithi nayo ejija kancane ingavula amathuba okulimala nokopha.

Eminye imithi eyehlisa ijubane ukuvala igazi ifaka phakathi i-aspirin, i-clopidogrel (i-Plavix), i-dalteparin (i-Fragmin), i-enoxaparin (i-Lovenox), i-heparin, i-indomethacin (i-Indocin), i-ticlopidine (i-Ticlid), i-warfarin (i-Coumadin), neminye.
I-Primidone (Mysoline)
I-Primidone (Mysoline) yehliswa ngumzimba. Kunokukhathazeka okuthile ngokuthi i-niacinamide ingahle yehle ukuthi umzimba wehla ngokushesha kangakanani i-primidone (Mysoline). Kepha alukho ulwazi olwanele ukwazi ukuthi ngabe lokhu kubalulekile.
Amakhambi nezithako ezingalimaza isibindi
I-Niacinamide ingadala ukulimala kwesibindi, ikakhulukazi uma isetshenziswa ngemithamo ephezulu. Ukuthatha i-niacinamide kanye namanye amakhambi noma izithasiselo ezingalimaza isibindi kungakhuphula le ngozi. Eminye yale mikhiqizo ifaka i-androstenedione, iqabunga le-borage, i-chaparral, i-comfrey, i-dehydroepiandrosterone (i-DHEA), i-germander, i-kava, i-pennyroyal oil, imvubelo ebomvu, neminye.
Amakhambi nezengezo ezinganciphisa ukujiya kwegazi
I-Niacinamide inganciphisa ukuvimba kwegazi. Ukusebenzisa i-niacinamide kanye namanye amakhambi nezithako ezengeza futhi nokuqina kwegazi kungakhuphula ingozi yokopha kwabanye abantu. Amanye amakhambi alolu hlobo afaka i-angelica, i-clove, i-danshen, i-garlic, i-ginger, i-Panax ginseng, namanye.
Akukho ukuxhumana okwaziwayo nokudla.
Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:
  • Jikelele: Eminye imikhiqizo yokwengeza yokudla ingahle ingabhali i-niacinamide ngokuhlukile kwilebula. Esikhundleni salokho, kungahle kubhalwe ngaphansi kwe-niacin. I-Niacin ilinganiswa ngokulingana kwe-niacin (NE). Umthamo we-1 mg we-niacinamide uyefana no-1 mg NE. Izibonelelo zokudla ezinconywayo zansuku zonke (ama-RDA) ze-niacinamide kubantu abadala zingama-16 mg NE kwabesilisa, i-14 mg NE yabesifazane, i-18 mg NE yabesifazane abakhulelwe, ne-17 mg NE yabesifazane abancelisayo.
  • OkwezindunaKusetshenziswe amaphilisi aqukethe i-750 mg ye-niacinamide, i-25 mg ye-zinc, i-1.5 mg yethusi, ne-500 mcg ye-folic acid (i-Nicomide) kanye noma kabili ngosuku. Futhi, amaphilisi ama-1-4 aqukethe i-niacinamide, i-azelaic acid, i-zinc, i-vitamin B6, ithusi ne-folic acid (i-NicAzel, i-Elorac Inc., i-Vernon Hills, i-IL) athathwe nsuku zonke.
  • Ngezimpawu zokuntuleka kukavithamini B3 njenge-pellagra: 300-500 mg ngosuku we-niacinamide unikezwa ngemithamo ehlukanisiwe.
  • Okwesifo sikashukela: Niacinamide 1.2 amagremu / m2 (indawo engaphezulu komzimba) noma i-25-50 mg / kg isetshenziswa nsuku zonke ukwehlisa ukukhula kohlobo lwesifo sikashukela sohlobo 1. Futhi, i-0.5 gram ye-niacinamide kathathu nsuku zonke isetshenziselwa ukunciphisa ukukhula kohlobo lwesifo sikashukela sohlobo 2.
  • Ngamazinga aphezulu e-phosphate egazini (hyperphosphatemia): I-Niacinamide kusuka ku-500 mg kuze kufike ku-1.75 amagremu nsuku zonke ngemithamo ehlukanisiwe isetshenziselwa amasonto ayi-8-12.
  • Ngomdlavuza we-larynx: 60 mg / kg ye-niacinamide inikezwa amahora ayi-1-1.5 ngaphambi kokuhogela i-carbogen (2% i-carbon dioxide kanye ne-98% oxygen) ngaphambi nangesikhathi se-radiotherapy.
  • Ngomdlavuza wesikhumba ngaphandle kwe-melanoma: 500 mg we-niacinamide kanye noma kabili nsuku zonke izinyanga eziyi-4-12.
  • Ukwelapha i-osteoarthritis: 3 amagremu we-niacinamide ngosuku ngemithamo ehlukanisiwe amasonto ayi-12.
ESIKHUMBINI:
  • Izinduna: Ijeli ene-4% niacinamide kabili ngosuku.
IZINGANE

  • Jikelele: Izibonelelo zokudla ezinconywayo zansuku zonke (ama-RDA) ze-niacinamide ezinganeni zingu-2 mg wezinsana ezinezinyanga ezineminyaka engu-0-6, i-4 mg NE yezinsana ezinezinyanga eziyi-7-12 ubudala, i-6 mg NE yezingane ezineminyaka engu-1-3, 8 I-mg NE yezingane ezineminyaka engu-4-8 ubudala, i-12 mg NE yezingane ezineminyaka engu-9-13 ubudala, i-16 mg NE yabesilisa abaneminyaka engu-14-18 ubudala, ne-14 mg NE yabesifazane abaneminyaka engu-14-18 ubudala.
  • OkwezindunaEzinganeni okungenani ezineminyaka engu-12 ubudala, amaphilisi ayi-1-4 aqukethe i-niacinamide, i-azelaic acid, i-zinc, i-vitamin B6, ithusi ne-folic acid (i-NicAzel, i-Elorac Inc., i-Vernon Hills, i-IL) athathwa nsuku zonke.
  • Okwe-pellagra: 100-300 mg we-niacinamide unikezwa nsuku zonke ngamanani ahlukanisiwe.
  • Yohlobo 1 sikashukela: 1.2 amagremu / m2 (indawo engaphezulu komzimba) noma i-niacinamide engu-25-50 mg / kg isetshenziswa nsuku zonke ukwehlisa ukukhula noma ukuvimbela uhlobo lwesifo sikashukela sohlobo 1.
3-Pyridine Carboxamide, 3-Pyridinecarboxamide, Amide de l'Acide Nicotinique, B Complex Vitamin, Complexe de Vitamines B, Niacinamida, Nicamid, Nicosedine, Nicotinamide, Nicotinic Acid Amide, Nicotylamidum, Pyridine-3-carboxamide Vitamin, , IVithamini B3.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.


  1. UZhang Y, Ma T, Zhang P. Ukusebenza nokuphepha kwe-nicotinamide ku-phosphorus metabolism kwiziguli ze-hemodialysis: Ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta. Imithi (iBaltimore). 2018; 97: e12731. Buka okungaqondakali.
  2. I-Cannizzaro MV, i-Dattola A, i-Garofalo V, i-Del Duca E, i-Bianchi L. Ukunciphisa imiphumela emibi yesikhumba somlomo: ukusebenza kahle kwe-8% omega-ceramides, ushukela we-hydrophilic, i-5% i-niacinamide cream compound ezigulini zomqubuko. G Ital iDermatol Venereol. 2018; 153: 161-164. Buka okungaqondakali.
  3. Isikhungo Sokuzivocavoca Kwemitholampilo e-NICE (UK). I-Hyperphosphataemia e-Chronic Kidney Disease: Ukuphathwa kwe-Hyperphosphataemia ezigulini ezineSigaba 4 noma 5 sezifo zezinso ezingamahlalakhona. I-National Institute for Health and Care Excellence: Imihlahlandlela Yomtholampilo. EManchester: Isikhungo Sikazwelonke Sezempilo Nokunakekelwa Kokunakekelwa (UK); 2013 Mashi.
  4. UCheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. Isivivinyo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo se-niacinamide sokwehliswa kwe-phosphorus ezigulini ze-hemodialysis. Umtholampilo J Am Soc Nephrol. 2008 Julayi; 3: 1131-8. Buka okungaqondakali.
  5. IHoskin PJ, iRojas AM, iBentzen SM, iSaunders MI. I-Radiotherapy ene-carbogen efanayo kanye ne-nicotinamide esinyeni i-carcinoma. J Clin Oncol. 2010 Nov 20; 28: 4912-8. Buka okungaqondakali.
  6. USurjana D, iHalliday GM, uMartin AJ, uMoloney FJ, uDamian DL. I-nicotinamide yomlomo inciphisa ama-actinic keratoses esigabeni II esivivinywa kabili esenziwe izimpumputhe. J Invest Dermatol. 2012 Kwangathi; 132: 1497-500. Buka okungaqondakali.
  7. U-Omidian M, Khazanee A, Yaghoobi R, Ghorbani AR, Pazyar N, Beladimousavi SS, Ghadimi M, Mohebbipour A, Feily A. Umphumela wokwelapha we-nicotinamide yomlomo ku-refurative uremic pruritus: isifundo esingahleliwe, esiyimpumputhe. I-Saudi J Kidney Dis Transpl. 2013 Septhemba; 24: 995-9. Buka okungaqondakali.
  8. UNijkamp MM, Span PN, Terhaard CH, Doornaert PA, Langendijk JA, van den Ende PL, de Jong M, van der Kogel AJ, Bussink J, uKaanders JH. Isichasiso se-Epidermal factor factor receptor kumdlavuza we-laryngeal ubikezela umphumela wokuguqulwa kwe-hypoxia njengesengezo ku-radiotherapy esheshayo esivivinyweni esilawulwa ngokungahleliwe. Umdlavuza we-Eur J. 2013 Okthoba; 49: 3202-9. Buka okungaqondakali.
  9. UMartin AJ, Chen A, Choy B, et al. I-nicotinamide yomlomo yokwehlisa umdlavuza we-actinic: Isigaba sesithathu sesilingo esilawulwa ngokungahleliwe esilawulwa kabili. J Clin Oncol 33, 2015 (suppl; abstr 9000).
  10. U-Lee DH, Oh IY, uKoo KT, uSuk JM, uJung SW, iPark JO, uKim BJ, uChoi YM. Ukwehliswa kwe-hyperpigmentation ebusweni ngemuva kokwelashwa ngenhlanganisela ye-niacinamide ne-tranexamic acid: isilingo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yimoto. Isikhumba Res Technol. 2014 Kwangathi; 20: 208-12. Buka okungaqondakali.
  11. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER. Isihloko esingu-4% nicotinamide vs. 1% i-clindamycin kuma-acne vulgaris alinganayo. I-Int J Dermatol. 2013 Aug; 52: 999-1004. Buka okungaqondakali.
  12. UJanssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Takes RP, de Bree R, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH. Ukusinda okuthuthukile kokuphindaphinda okungenayo ne-ARCON yeziguli ezingenagciwane ezinomdlavuza we-laryngeal. ICancer Cancer Res. 2014 uMar 1; 20: 1345-54. Buka okungaqondakali.
  13. UJanssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH. I-radiotherapy esheshayo nge-carbogen ne-nicotinamide yomdlavuza we-laryngeal: imiphumela yesivivinyo sesigaba III esingahleliwe. J Clin Oncol. 2012 Meyi 20; 30: 1777-83. Buka okungaqondakali.
  14. UFabbrocini G, uCantelli M, uMonfrecola G.I-topical nicotinamide ye-seborrheic dermatitis: isifundo esivulwe ngokungahleliwe. Ukuphathwa kwe-J Dermatolog. 2014 Juni; 25: 241-5. Buka okungaqondakali.
  15. U-Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, Hoskin PJ, West CM. I-Necrosis ibikezela ukuthi izosizakala ekwelashweni kokuguqula i-hypoxia ezigulini ezinomdlavuza omkhulu wesinye esengozini enkulu ebhaliswe esivivinyweni sesigaba III esingahleliwe. I-Radiother Oncol. 2013 Julayi; 108: 40-7. Buka okungaqondakali.
  16. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA. Ukuvinjelwa kwe-Sirtuin ne-pan-class I / II deacetylase (DAC) kuhambisana kumamodeli wangaphambi kokuhlolwa kanye nezifundo zokwelashwa ze-lymphoma. Igazi. 2013 Sep 19; 122: 2104-13. Buka okungaqondakali.
  17. UShalita AR, u-Falcon R, u-Olansky A, u-Iannotta P, u-Akhavan A, uSuku D, uJaniga A, uSingri P, uKallal JE. Ukuphathwa kwama-acne okuvuvukala nge-supplement kadokotela yokudla. J Izidakamizwa Dermatol. 2012; 11: 1428-33. Buka okungaqondakali.
  18. UFalsini, B., Piccardi, M., Iarossi, G., Fadda, A., Merendino, E., noValentini, P. Umthelela wesengezo esifushane se-antioxidant ekusebenzeni kwe-macular ku-maculopathy ehlobene nobudala: isifundo somshayeli kubandakanya ukuhlolwa kwe-electrophysiologic. I-Ophthalmology 2003; 110: 51-60. Buka okungaqondakali.
  19. U-Elliott RB, uPilcher CC, uStewart A, uFergusson D, uMcGregor MA. Ukusetshenziswa kwe-nicotinamide ekuvikeleni uhlobo lwesifo sikashukela sohlobo 1. U-Ann N Y Acad Sci. 1993; 696: 333-41. Buka okungaqondakali.
  20. URottembourg JB, uLaunay-Vacher V, uMassard J. Thrombocytopenia obangelwa yi-nicotinamide ezigulini ze-hemodialysis. Izinso Int. 2005; 68: 2911-2. Buka okungaqondakali.
  21. UTakahashi Y, Tanaka A, uNakamura T, et al. INicotinamide icindezela i-hyperphosphatemia ezigulini ze-hemodialysis. Izinso Int. 2004; 65: 1099-104. Buka okungaqondakali.
  22. USoma Y, Kashima M, Imaizumi A, et al. Imiphumela ethambisa i-nicotinamide yama-topical esikhunjeni esomile se-atopic. I-Int J Dermatol. 2005; 44: 197-202. Buka okungaqondakali.
  23. UPowell ME, Hill SA, Saunders MI, Hoskin PJ, uChaplin DJ. Ukuhamba kwegazi lesigaxa somuntu kuthuthukiswa yi-nicotinamide nokuphefumula kwe-carbogen. Umdlavuza Res. 1997; 57: 5261-4. Buka okungaqondakali.
  24. IHoskin PJ, Rojas AM, uPhillips H, uSaunders MI. Ukugula okuphuzile nokwelashwa sekwephuzile ekwelapheni i-advanced bladder carcinoma nge-radiotherapy esheshayo, i-carbogen, ne-nicotinamide. Umdlavuza. 2005; 103: 2287-97. Buka okungaqondakali.
  25. INiren NM, iTorok HM. Ukuthuthukiswa kweNicomide Ekufundweni Kwemiphumela Yomtholampilo (i-NICOS): imiphumela yesivivinyo samaviki angu-8. Ama-Cutis. 2006; 77 (1 Isipele): 17-28. Buka okungaqondakali.
  26. UKamal M, Abbasy AJ, Muslemani AA, Bener A. Umphumela we-nicotinamide ezinganeni ezisanda kutholakala zesifo sikashukela sohlobo 1. I-Acta Pharmacol Sin. 2006; 27: 724-7. Buka okungaqondakali.
  27. I-Olmos PR, uHodgson MI, Maiz A, et al. INicotinamide ivikele impendulo yesigaba sokuqala se-insulin (FPIR) futhi yavimbela isifo semitholampilo ezihlotsheni zokuqala zabahlobo besifo sikashukela sohlobo 1. Isifo Sikashukela Res Clin Pract. 2006; 71: 320-33. Buka okungaqondakali.
  28. IGale EA, iBingley PJ, i-Emmett CL, iCollier T; Iqembu le-European Nicotinamide Diabetes Intervention Trial (ENDIT). I-European Nicotinamide Diabetes Intervention Trial (ENDIT): isilingo esilawulwa ngokungahleliwe sokungenelela ngaphambi kokuqala kohlobo lwesifo sikashukela sohlobo 1. I-Lancet. 2004; 363: 925-31. Buka okungaqondakali.
  29. UCabrera-Rode E, uMolina G, u-Arranz C, uVera M, et al. Umphumela we-nicotinamide ejwayelekile ekuvikeleni isifo sikashukela sohlobo 1 ezihlotsheni zokuqala zezihlobo zabantu abanesifo sikashukela sohlobo 1. Ukuzilimaza. 2006; 39: 333-40. Buka okungaqondakali.
  30. UHakozaki T, Minwalla L, Zhuang J, et al. Umphumela we-niacinamide ekwehliseni i-pigmentation cutaneous kanye nokucindezelwa kokudluliswa kwe-melanosome. Br J Dermatol. 2002 Julayi; 147: 20-31. Buka okungaqondakali.
  31. IBissett DL, Oblong JE, iBergge CA. I-Niacinamide: Uvithamini B owenza ngcono ukubukeka kwesikhumba ebusweni. Ukuhlinzwa kweDermatol. 2005; 31 (7 Pt 2): 860-5; ingxoxo 865. Buka okungaqondakali.
  32. UJorgensen J. Pellagra mhlawumbe kungenxa ye-pyrazinamide: ukukhula ngesikhathi se-chemotherapy ehlangene yesifo sofuba. I-Int J Dermatol 1983; 22: 44-5. Buka okungaqondakali.
  33. USwash M, uRoberts AH. I-pellagra efana ne-encephalopathy efana ne-ethionamide ne-cycloserine. I-Tubercle 1972; 53: 132. Buka okungaqondakali.
  34. I-Brooks-Hill RW, uMbhishobhi ME, uVellend H. Pellagra-like encephalopathy efaka uxhaxha lwemithi eminingi yokwelapha ukutheleleka kwamaphaphu ngenxa ye-Mycobacterium avium-intracellulare (incwadi). NginguRev Rev Dis Dis 1985; 131: 476. Buka okungaqondakali.
  35. UVisalli N, uCavallo MG, uSignore A, et al. Isivivinyo esinezikhungo eziningi eziningi semithamo emibili ehlukene ye-nicotinamide ezigulini ezinesifo sikashukela sohlobo lokuqala esisanda kuqala (i-IMDIAB VI). Isifo Sikashukela Metab Res 1999; 15: 181-5. Buka okungaqondakali.
  36. IBourgeois BF, uDodson WE, uFerrendelli JA. Ukusebenzisana phakathi kwe-primidone, carbamazepine, ne-nicotinamide. I-Neurology 1982; 32: 1122-6. Buka okungaqondakali.
  37. Ubaba CM. I-Niacinamide ne-acanthosis nigricans (incwadi). I-Arch Dermatol 1984; 120: 1281. Buka okungaqondakali.
  38. Ubusika SL, uBoyer JL. Ubuthi be-hepatic obuvela emithamo emikhulu kavithamini B3 (nicotinamide). N Engl J Med 1973; 289: 1180-2. Buka okungaqondakali.
  39. UMcKenney J. Imibono emisha ngokusetshenziswa kwe-niacin ekwelapheni ukuphazamiseka kwe-lipid. I-Arch Intern Med 2004; 164: 697-705. Buka okungaqondakali.
  40. Ukukhulisa i-HDL nokusetshenziswa kwe-Niacin. Incwadi ka-Pharmacist's Letter / Prescriber's 2004; 20: 200504.
  41. IHoskin PJ, iStratford MR, iSaunders MI, et al. Ukuphathwa kwe-nicotinamide phakathi kweshadi: i-pharmacokinetics, ukukhuphuka komthamo, nobuthi bomtholampilo. I-Int J Radiat Oncol Biol Phys 1995; 32: 1111-9. Buka okungaqondakali.
  42. UFatigante L, uDucci F, uCartei F, et al. I-Carbogen ne-nicotinamide kuhlanganiswe ne-radiotherapy engajwayelekile ku-glioblastoma multiforme: ukwelashwa okusha kokuziphatha. I-Int J Radiat Oncol Biol Phys 1997; 37: 499-504. Buka okungaqondakali.
  43. UMiralbell R, uMornex F, uGreiner R, et al. I-radiotherapy esheshayo, i-carbogen, ne-nicotinamide ku-glioblastoma multiforme: umbiko we-European Organisation for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999; 17: 3143-9. Buka okungaqondakali.
  44. Anon. I-Niacinamide Monograph. I-Alt Med Rev 2002; 7: 525-9. Buka okungaqondakali.
  45. IHaslam RH, iDalby JT, iRademaker AW. Imiphumela yokwelashwa kwe-megavitamin ezinganeni ezinenkinga yokunganaki. Izifo zezingane 1984; 74: 103-11 .. Buka okungaqondakali.
  46. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, neCholine. IWashington, DC: National Academy Press, 2000. Itholakala ku: http://books.nap.edu/books/0309065542/html/.
  47. UShalita AR, uSmith JG, uPherish LC, et al. I-topical nicotinamide eqhathaniswa nejel clindamycin ekwelapheni i-acne vulgaris. I-Int J Dermatol 1995; 34: 434-7. Buka okungaqondakali.
  48. UMcCarty MF, uRussell AL. Ukwelashwa kwe-Niacinamide ye-osteoarthritis - ingabe kuvimbela ukwenziwa kwe-nitric oxide synthase nge-interleukin 1 kuma-chondrocyte? I-Med Hypotheses 1999; 53: 350-60. Buka okungaqondakali.
  49. UJonas WB, uRapoza CP, uBlair WF. Umphumela we-niacinamide ku-osteoarthritis: isifundo somshayeli. I-Inflamm Res 1996; 45: 330-4. Buka okungaqondakali.
  50. Polo V, Saibene A, Pontiroli AE. I-Nicotinamide ithuthukisa uketshezi lwe-insulin nokulawulwa komzimba emzimbeni weziguli ezi-2 ezinesifo sikashukela ngokwehluleka kwesibili kwe-sulphonylureas. I-Acta Diabetol 1998; 35: 61-4. Buka okungaqondakali.
  51. IGreenbaum CJ, iKahn SE, iPalmer JP. Imiphumela kaNicotinamide ku-glucose metabolism ezifundweni ezisengozini ye-IDDM. Isifo sikashukela 1996; 45: 1631-4. Buka okungaqondakali.
  52. UPozzilli P, uBrowne PD, uKolb H. Meta-ukuhlaziywa kokwelapha i-nicotinamide ezigulini ezine-IDDM ezisanda kuqala. Izilingo zeNicotinamide. Ukunakekelwa yisifo sikashukela 1996; 19: 1357-63. Buka okungaqondakali.
  53. UPozzzilli P, Visalli N, Signore A, et al. Isilingo esiphindwe kabili se-nicotinamide ku-IDDM yakamuva (isifundo se-IMDIAB III). Isifo sikashukela 1995; 38: 848-52. Buka okungaqondakali.
  54. UVisalli N, uCavallo MG, uSignore A, et al. Isivivinyo esinezikhungo eziningi eziningi semithamo emibili ehlukene ye-nicotinamide ezigulini ezinesifo sikashukela sohlobo lokuqala esisanda kuqala (i-IMDIAB VI). Isifo Sikashukela Metab Res 1999; 15: 181-5. Buka okungaqondakali.
  55. UPozzzilli P, uVisalli N, uCavallo MG, et al. I-Vitamin E ne-nicotinamide zinemiphumela efanayo ekugcineni ukusebenza kweseli ye-beta cell ekuqaleni kwesifo sikashukela esincike ku-insulin. I-Eur J Endocrinol 1997; 137: 234-9. Buka okungaqondakali.
  56. ILampeter EF, iKlinghammer A, iSherbaum WA, et al. Ucwaningo Lokungenelela lweDeutsche Nicotinamide: umzamo wokuvimbela uhlobo lwesifo sikashukela sohlobo 1. Iqembu le-DENIS. Isifo sikashukela 1998; 47: 980-4. Buka okungaqondakali.
  57. U-Elliott RB, Pilcher CC, Fergusson DM, uStewart AW. Isu elisekelwe kubantu ukuvimbela isifo sikashukela esincike ku-insulin sisebenzisa i-nicotinamide. UJ Pediatr Endocrinol Metab 1996; 9: 501-9. Buka okungaqondakali.
  58. IGale EA. Ithiyori kanye nokwenza kwezivivinyo ze-nicotinamide ku-pre-type 1 diabetes. UJ Pediatr Endocrinol Metab 1996; 9: 375-9. Buka okungaqondakali.
  59. I-Kolb H, iBurkart V. Nicotinamide kuhlobo 1 lwesifo sikashukela. Indlela yesenzo iphinde yabuyekezwa. Ukunakekelwa yisifo sikashukela 1999; 22: B16-20. Buka okungaqondakali.
  60. I-American Society of Health-System Pharmacists. Isitatimende Sesikhundla Sokwelashwa se-ASHP ngokusetshenziswa okuphephile kwe-niacin ekuphathweni kwe-dyslipidemias. NginguJ J Health Syst Pharm 1997; 54: 2815-9. Buka okungaqondakali.
  61. UGarg A, uGundundy SM. I-Nicotinic acid njengokwelashwa kwe-dyslipidemia kwisifo sikashukela esingancikile ku-insulin. I-JAMA 1990; 264: 723-6. Buka okungaqondakali.
  62. I-Crouse JR III. Intuthuko entsha ekusetshenzisweni kwe-niacin ekwelapheni i-hyperlipidemia: ukucatshangelwa okusha ekusetshenzisweni kwesidakamizwa esidala. ICoron Artery Dis 1996; 7: 321-6. Buka okungaqondakali.
  63. I-Brenner A. Imiphumela yama-megadoses wamavithamini ayinkimbinkimbi B akhethiwe ezinganeni ezine-hyperkinesis: izifundo ezilawulwayo ezinokulandelwa kwesikhathi eside. J Funda ukukhubazeka 1982; 15: 258-64. Buka okungaqondakali.
  64. I-Yates AA, iSchlicker SA, iSuitor CW. Ukufakwa kwereferensi yokudla: Isisekelo esisha sezincomo ze-calcium nezakhi ezihlobene, amavithamini B, ne-choline. J Am Ukudla Assoc 1998; 98: 699-706. Buka okungaqondakali.
  65. I-Shils ME, u-Olson JA, uShike M, uRoss AC, ama-eds. Ukondleka Kwamanje Ezempilo Nezifo. Umhlaka 9. IBaltimore, MD: Williams & Wilkins, 1999.
  66. IHarvengt C, Desager JP. Ukwanda kwe-HDL-cholesterol ezifundweni ze-normolipaemic ku-khellin: isifundo somshayeli. I-Int J Clin Pharmacol Res 1983; 3: 363-6. Buka okungaqondakali.
  67. UHardman JG, uLimbird LL, uMolinoff PB, ama-eds. UGoodman noGillman’s The Pharmacological Basis of Therapeutics, umhla ka-9. ENew York, NY: McGraw-Hill, 1996.
  68. UMcEvoy GK, umhleli. Imininingwane Yezidakamizwa ze-AHFS. I-Bethesda, MD: I-American Society of Health-System Pharmacists, ngo-1998.
  69. UBlumenthal M, u-ed. I-Complete German Commission E Monographs: Umhlahlandlela Wezokwelapha Emithini Yemithi. I-Trans. S. Klein. IBoston, MA: Umkhandlu Wezamabhodlela waseMelika, ngo-1998.
Kugcine ukubuyekezwa - 10/05/2020

Inconyelwe Kuwe

Ileostomy - ukushintsha isikhwama sakho
Umuthi

Ileostomy - ukushintsha isikhwama sakho

Ubunokulimala noma i ifo ohlelweni lwakho lokugaya ukudla futhi udinga ukuhlinzwa okubizwa nge-ileo tomy. Ukuhlinzwa ku hint he indlela umzimba wakho ulahla ngayo imfucuza (indle, indle noma indle).Ma...
Indololwane yethenisi
Umuthi

Indololwane yethenisi

Indololwane yetheni i kuba buhlungu noma ubuhlungu ngaphandle (emaceleni) ohlangothini olungaphezulu nga endololwaneni.Ingxenye yemi ipha enamathela ethanjeni ibizwa ngokuthi yi-tendon. Eminye imi iph...